Meprin metalloproteases: Molecular regulation and function in inflammation and fibrosis

Meprin metalloproteases: Molecular regulation and function in inflammation and fibrosis

    Meprin Metalloproteases: Molecular Regulation and Function in Inflammation and Fibrosis Philipp Arnold, Anna Otte, Christoph Becker-P...

1MB Sizes 1 Downloads 57 Views

    Meprin Metalloproteases: Molecular Regulation and Function in Inflammation and Fibrosis Philipp Arnold, Anna Otte, Christoph Becker-Pauly PII: DOI: Reference:

S0167-4889(17)30122-2 doi:10.1016/j.bbamcr.2017.05.011 BBAMCR 18097

To appear in:

BBA - Molecular Cell Research

Received date: Revised date: Accepted date:

18 April 2017 5 May 2017 9 May 2017

Please cite this article as: Philipp Arnold, Anna Otte, Christoph Becker-Pauly, Meprin Metalloproteases: Molecular Regulation and Function in Inflammation and Fibrosis, BBA - Molecular Cell Research (2017), doi:10.1016/j.bbamcr.2017.05.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT Meprin Metalloproteases: Molecular Regulation and Function in Inflammation and Fibrosis

IP

T

Philipp Arnold1, Anna Otte2, Christoph Becker-Pauly2#

1

SC R

Institute of Anatomy, University of Kiel, Germany

2

NU

Unit for Degradomics of the Protease Web, Institute of Biochemistry, University of Kiel, Germany

#

MA

Correspondence: [email protected]

D

Abstract

TE

The zinc-endopeptidases meprin α and meprin β are extracellular proteases involved in connective tissue homeostasis, intestinal barrier function and immunological processes. Meprins are unique amongst other extracellular proteases with regard to cleavage specificity

CE P

and structure. Meprin α and meprin β have a strong preference for negatively charged amino acids around the scissile bond, reflected by cleavage sites identified in procollagen I, the amyloid precursor protein (APP) and the interleukin-6 receptor (IL-6R). In this review we report

AC

on recent findings that summarize the complex molecular regulation of meprins, particular folding, activation and shedding. Dysregulation of meprin α and meprin β is often associated with pathological conditions such as neurodegeneration, inflammatory bowel disease and fibrosis. Based on mouse models and patient data we suggest meprins as possible key regulators in the onset and progression of fibrotic disorders, leading to severe diseases such as pulmonary hypertension.

1

ACCEPTED MANUSCRIPT Introduction Chronic Inflammation is often associated with additional pathological conditions, such as

T

cancer and fibrosis (Coulouarn and Clement, 2014). Many genes have been identified to either

IP

contribute to the onset or progression of these diseases. Some of these may represent key

SC R

regulators, thereby connecting chronic inflammation and tissue remodeling that finally results in a pathological phenotype. Metalloproteases meprin α and meprin β represent such regulatory factors. For instance, both enzymes were shown to have pro-inflammatory activity,

NU

they contribute to extracellular matrix (ECM) remodeling, and importantly their expression is upregulated in chronic inflammation, certain cancers, and fibrosis (Broder and Becker-Pauly,

MA

2013, Prox et al., 2015).

A well described physiological function of meprins is the maturation of fibrillar procollagens I

D

and III through cleavage of the N- and C-terminal prodomains (Broder et al., 2013, Kronenberg

TE

et al., 2010). This proteolytic event is a prerequisite for collagen fibril assembly, and explains why decreased meprin expression leads to impaired connective tissue, whereas upregulation

CE P

of the proteases is associated with fibrosis (Prox et al., 2015). Hence, meprins may be considered as therapeutic targets in future studies. However, it is not yet clear whether meprins are solely involved in ECM remodeling that triggers

AC

the symptoms of the disease, or additionally in the preceding inflammatory step that induces the onset of fibrosis. Several studies revealed pro- as well as anti-inflammatory activity of meprins (Broder and Becker-Pauly, 2013). The function of meprin metalloproteases clearly depends on their cellular localization. One example for a biological function of meprin β on the apical side of intestinal epithelial cells is the constitutive mucus detachment that prevents bacterial overgrowth (Schutte et al., 2014). Hence, meprin β activity in the intestinal lumen is important for barrier function and prevents bacterial infection. However, when inflammation occurs, meprin β at the mesenchymal site can induce pro-inflammatory stimulus, e.g. by cleaving the IL-6R to induce IL-6 trans-signaling (Arnold et al., 2017a). Several factors that regulate localization, activation and inhibition of meprins have been discovered over the last years. We have learned that not only transcriptional regulation, as 2

ACCEPTED MANUSCRIPT shown for AP-1 and meprin β (Biasin et al., 2014), is important to characterize protease function. Different proteases are expressed in very diverse amounts, but this does not equally correlate with proteolytic activity towards certain substrates. For instance, BACE-1, the well-

IP

T

known β-secretase for APP, is highly expressed in neurons and additionally up-regulated in Alzheimer’s disease (Vassar et al., 2014). Meprin β, also reported to generate Aβ peptides, is

SC R

present at much lower concentrations in the brain. However, in vitro kinetic studies revealed that meprin β exhibited a 104- and 103-fold higher catalytic efficiency toward APP-peptide

NU

substrates when compared to BACE-1 (Bien et al., 2012). Additionally, APP is cleaved by meprin β already in the late Golgi and at the cell surface (Schonherr et al., 2016), whereas

MA

BACE-1 cleaves after internalization of APP in acidic endosomal compartments (Vassar et al., 2014). Thus, besides the transcriptional regulation of a protease, cleavage kinetics and subcellular localization of enzymes are also of importance for the proteolytic turnover of

D

substrates. Additional factors that regulate substrate proteolysis are endogenously occurring

TE

activators and inhibitors of proteases. Taken together, this so called ‘protease web’ (Fortelny

CE P

et al., 2014) builds the microenvironment that is important to understand proteolysis as a regulatory event in pathophysiology. In this review we summarize recent findings that explain how the metalloproteases meprin α

fibrosis.

AC

and meprin β are orchestrated in the protease web and how this influences inflammation and

Regulatory mechanisms influencing meprin activity The metalloproteases meprin α and meprin β have important physiological functions and can be dysregulated in certain associated pathologies. Hence, a detailed understanding of the regulation of these proteases may help to evaluate their therapeutic potential. In a recent study it was shown that the oncoprotein Reptin strongly regulates the expression of meprin α (Breig et al., 2017). For meprin β the AP-1 transcription factor complex was found to stimulate gene expression, which contributes to the onset and progression of fibrosis (Biasin et al., 2014). Over the last years, multiple factors that influence folding, cellular localization and activation 3

ACCEPTED MANUSCRIPT of meprins have been described. Meprin α is constitutively released into the extra cellular space as it is cleaved by furin within its inserted domain (Marchand et al., 1995) (Fig. 1A). This domain is absent in meprin β, which makes the protease primarily membrane-bound. However,

IP

T

it was shown that meprin β can be shed from the cell surface by ADAM 10/17, resulting in a soluble form of meprin β (Jefferson et al., 2013, Hahn et al., 2003). In the following, three new

SC R

major findings on meprin β regulation will be addressed: i) activation of membrane-bound meprin β by the membrane-bound serine protease matriptase-2, ii) the interaction with

NU

tetraspanin 8 and iii) the influence of calcium ions on protein folding and activity. Shedding and activation of meprin α and meprin β

MA

Like most proteolytic enzymes meprin α and meprin β are expressed as zymogens and require activation through other proteases. Several tryptic serine proteases can activate both pro-

D

forms by cleaving human meprin α between arginine 65 and asparagine 66 and meprin β

TE

between arginine 61 and asparagine 62 (Ohler et al., 2010) (Fig. 1B). Large parts of the meprin

CE P

α and meprin β ectodomain are composed of identical domains. For meprin β these were crystalized and atomically resolved structures are available for the latent and active protease (Arolas et al., 2012). The crystal structures contain the protease domain (with or without the

AC

pro-peptide), the MAM (meprin A5 protein tyrosine phosphatase μ) domain and the TRAF (tumour-necrosis-factor-receptor-associated factor) domain. The only extracellular region missing in the crystal structure is the EGF-like domain, which is localized C-terminal to the TRAF domain and connects the extracellular part of meprin β to the transmembrane helix (Fig. 1A). Interestingly, meprins are the only proteins containing an extracellular TRAF domain. The crystal structures helped to elucidate the general orientation of membrane-bound meprin β at the cell surface and it became evident that the activation site is in close proximity to the membrane (Arolas et al., 2012) (Fig. 1B). Despite the almost identical domain composition there is one decisive difference between meprin α and meprin β. Meprin α contains an additional inserted domain between the TRAF and the EGF-like domain that is cleaved by furin (or other proprotein convertases) on the secretory pathway (Marchand et al., 1995). Thus, 4

ACCEPTED MANUSCRIPT meprin α is constitutively released into the extracellular space as a soluble protease. Additionally, meprin α forms large, non-covalently linked oligomers up to 6.4 MDa, by a so far unknown mechanism (Bertenshaw et al., 2003, Becker et al., 2003). Of note, meprin α is the

IP

T

largest extracellular protease known, concentrating high proteolytic activity in its oligomeric state.

SC R

Different soluble serine proteases have been described for shed meprin α and meprin β that cleave off the pro-peptide and thereby induce proteolytic activity. Pancreatic trypsin and tissue

NU

kallikrein related peptidase (KLK) 5 activate both proteases (Ohler et al., 2010). Meprin α is exclusively activated by plasmin and meprin β by KLKs 4 and 8 (Rosmann et al., 2002). This

MA

might be of physiological importance in the small intestine as it was shown that the release of meprin β by its sheddases ADAM10/17 is important for proteolytic processing of the mucus protein mucine 2 (Muc2) (Schutte et al., 2014). Interestingly, substrates are differentially

D

cleaved by membrane-bound and soluble meprin β. For the APP it was shown that only

TE

membrane-bound meprin β cleaves at the β-secretase site but not the shed protease (Bien et

CE P

al., 2012). The same holds true for the IL-6R where only membrane-bound meprin β acts as a sheddase, whereas soluble meprin β exerts no proteolytic activity towards this substrate (Arnold et al., 2017a). Interestingly, the constitutive soluble meprin α can cleave the IL-6R and

AC

generates, as the membrane-bound meprin β, soluble IL-6R capable of trans-signaling. To exert proteolytic activity, activation of meprin β at the cell surface has to occur. Therefore, potential membrane-bound activators have been investigated. With the membrane-tethered serine protease matriptase-2 (MT-2), such an activator could be identified (Jackle et al., 2015). The favored maturation of meprin β by MT-2 was observed in immunoblot analysis and in activity measurements employing a specific fluorogenic peptide cleavage assay. Additionally, co-transfection of meprin β with MT-2 resulted in an appreciable decrease in soluble APPα, which correlates with increased β-secretase activity. In vivo, both proteases co-localize at the cell surface and were found on immune cells in the lamina propria of the small intestine. Activation of meprin β by MT-2 is a specific event as several other membrane-bound tryptic proteases tested did not activate the membrane-bound meprin β. 5

ACCEPTED MANUSCRIPT Meprin β is localized in tetraspanin enriched microdomains At the cell surface, the localization of protease and substrate is of critical importance. We have

T

learned that meprins can exist as membrane-bound or soluble proteins, which are then

IP

differentially activated and exhibit distinctive substrate repertoires. To regulate localization and

SC R

activity of a protease, interaction with other proteins, which are not necessarily proteolytic targets, can be important. One example is the regulation of ADAM17 by inactive rhomboids 1 and 2 (iRhom1/2) (McIlwain et al., 2012, Adrain et al., 2012). It was shown that iRhoms interact

NU

with ADAM17 in the endoplasmic reticulum and facilitate its transport via the Golgi compartment to the cell surface. Additionally, several tetraspanins (TSPANs) were shown to

MA

interact with ADAM proteases, building clusters of TSPAN enriched microdomains (TEMs) (Matthews et al., 2016). Identification of such non-proteolytic interaction partners helps to

D

understand protease transport, cellular localization and substrate cleavage. Meprin β is highly

TE

expressed in the small intestine and is exclusively localized at the apical side of enterocytes. For the identification of non-proteolytic interaction partners we employed a yeast two-hybrid

CE P

screen using an intestinal cDNA library. Here, TSPAN8 was found to specifically interact with meprin β in TEMs (Schmidt et al., 2016). Interestingly, APP was additionally detected in these

AC

TEMs demonstrating a likely interaction of protease and substrate in well-organized cell surface microdomains. This is in contrast to the major β-secretase BACE1, which cleaves APP in early endosomes (Vassar et al., 2014). It will be important to decipher additional non-proteolytic interaction partners of meprin α and meprin β that determine cellular localization, substrate interaction and half-life at the cell membrane. Folding and activity of meprin β is influenced by calcium Cleavage is abrogated in the presence of high calcium concentrations for different substrates of meprin β, such as Muc2 (Schutte et al., 2014) and the dentin sialo phosphoprotein (DSPP) (Arnold et al., 2017b, Tsuchiya et al., 2011). In these studies, the influence of calcium was attributed to substrate modification. In 2015 we showed that there may be a direct influence of 6

ACCEPTED MANUSCRIPT calcium on the proteolytic activity of meprin β (Arnold et al., 2015). Here, in the presence of calcium, a decreased activity of meprin β towards a fluorogenic peptide substrate and APP was observed. Through analysis of the structural properties of meprin β a potential calcium

IP

T

binding site was detected, which is composed of amino acids aspartate 204 (D204), aspartate 245 (D245), glutamate 163 (E163) and serine 242 (S242) (Fig. 1C). Mutation of D204 and

SC R

D245 to alanine led to largely misfolded proteins that could not exit the ER or were found in large intracellular vesicles, respectively. Thus, we concluded that meprin β might require

NU

calcium for proper folding. This is further supported by molecular dynamics simulation where active meprin β is gradually transferred into a pro-meprin β-like conformation under increasing

MA

calcium concentrations (Schneppenheim et al., 2017). Further increase of calcium resulted in an unfolded meprin β with two calcium ions bound in the proposed binding motif. Indeed, meprin β can be inhibited by calcium, with an inhibition constant (Ki) of 11.5 mM CaCl2. The

D

physiological extracellular calcium concentration however, is between 2.1-2.8 mM, which is

TE

not sufficient to inhibit meprin β. Local calcium concentrations can eventually be higher as

CE P

found for example in bone or teeth (Somlyo et al., 1985). As bone and tooth dentin are both composed of a mineralized collagen I, meprins were discussed to play an important role there for pro-collagen maturation. For bone it was already shown that another pro-collagen

AC

converting enzyme, the bone morphogenetic protein 1 (BMP-1), seems to be of critical importance (Muir et al., 2014). Here a postnatal knockout of BMP-1 in mice resulted in the development of an osteogenesis imperfecta-like phenotype with deficient mineralization of bone tissue. The tendon and connective tissue of these mice however appeared not to be affected, despite the fact that they consist of large amounts of fibrillar collagens. Mice deficient for meprin α or meprin β on the other hand exhibit diminished collagen deposition and tensile strength in the skin (Broder et al., 2013). Again, in the presence of high calcium concentrations, there is no phenotype observed in meprin α or meprin β knock-out animals in tooth development and maintenance. In these mice developing or mature dentin was found to be normal (Arnold et al., 2017b). However, a strong phenotype could be described in mice deficient for BMP-1 and its close relative tolloid-like 1 (TLL1). Here, a severe defect in postnatal 7

ACCEPTED MANUSCRIPT root dentin formation and a partially impaired periodontal ligament homeostasis was detected (Wang et al., 2017). However, there was still a certain amount of maturated collagen, thus indicating that other proteases may partially compensate for the loss of BMP-1 and TLL1.

IP

T

In conclusion meprin β is directly influenced by calcium ions, most likely through binding to the catalytic domain complexed by a cluster of charged amino acid residues. Consequently,

SC R

meprin β plays no significant role in collagen maturation in calcium-rich tissues such as bone or dentin, but has important physiological functions in other compartments. Characterization

NU

of meprins’ substrate specificity, structural properties and other regulatory elements is

AC

CE P

TE

D

MA

important to understand their role in the onset and/or progression of disease.

8

AC

CE P

TE

D

MA

NU

SC R

IP

T

ACCEPTED MANUSCRIPT

Figure 1: Structural properties of meprin metalloproteases. A) Domain structure of meprin α and meprin β. Both consist of a pro-peptide that shields the active site of the protease domain. The protease domain is followed by a MAM-, a TRAF-, and an EGF-like domain. The proteases are membrane anchored via a transmembrane domain and contain a small C-terminal tail. Meprin α contains an additional inserted-domain that is cleaved by furin on the secretory pathway and leads to the release of meprin α into the extracellular space. By an unknown process meprin α forms large oligomers that can be observed by transmission electron microscopy. B) Meprin β is a membrane-bound dimer and the activation site is located between arginine 61 (Arg61) and asparagine 62. Additionally, tetraspanin 8 is shown to interact with meprin β in tetraspanin enriched microdomains. Furthermore, matriptase-2, the first known membrane-bound activator of meprin β, is shown. C) Structure of the active meprin β

9

ACCEPTED MANUSCRIPT protease domain with the active site oriented to the left. The Zinc ion (orange) and the Zinc ion coordinating histidine residues (cyan) are displayed. Additionally, asparagine 62 (N62), glutamate 163 (E163), aspartate 204 and 245 (D204 and D245), and lysine 248 (K248) are shown in magnification. These residues were shown to be involved in correct protein folding and activation after pro-peptide

IP

T

cleavage.

SC R

Meprins in inflammation and fibrotic diseases

Today it is widely accepted that excessive ECM turnover and deposition is tightly connected

NU

with chronic inflammatory disease. Initiation of an innate immune response is a necessary physiological process that can be induced by infections, mechanical stress or reactive oxygen

MA

species. Normally, this inflammatory process is resolved over time and the tissue returns to normal homeostasis. Under certain conditions however, the inflammation persists resulting in

D

a pathological chronic inflammatory response. Most chronic inflammation is accompanied by

TE

the deposition of excess amounts of ECM, including large portions of collagen I, referred to as fibrosis (Trojanowska et al., 1998, Bhogal et al., 2005). Initiation of fibrosis is marked by an

CE P

imbalance of pro- and anti-fibrotic cytokine profiles following the infiltration of mononuclear cells upon inflammation. Additionally, excessive ECM turnover by different proteases further drives inflammatory responses, which illustrates the interdependency of inflammation, tissue

AC

remodeling and matrix deposition. Sustained persistence of these processes and subsequent tissue scaring impairs proper organ function and may lead to complete organ failure. Over the last years, an array of proteins was described as substrates for meprins which are known to be involved in inflammatory disease and ECM remodeling (Tab. 1). Here, we highlight central events during inflammation and fibrosis that may be directly influenced by meprins.

10

ACCEPTED MANUSCRIPT Table 1: In vivo substrates of meprin α and meprin β and potential biological functions. Substrates

Meprin α/β

Function

Literature

Meprin α Meprin β

Fibrillar collagen deposition in connective tissue of the skin and lung

Broder et al., 2013, PNAS Biasin et al., 2016, Sci Rep

Mucin 2

Meprin β

Main component of the intestinal mucus layer, important for host barrier function

Schütte et al., 2014, PNAS

APP

Meprin β

APP-derived Aβ peptides are associated with the onset and progression of Alzheimer’s disease

Schönherr et al., 2016, Mol Neurodegen Jefferson et al., 2011, J Biol Chem

IL-6 receptor

Meprin α Meprin β

Mediator of pro-inflammatory IL6 trans-signaling

IL-6

Meprin α Meprin β

Cleavage of IL-6 and possible inactivation; increased IL-6 serum levels in meprin-deficient mice

Banerjee et al., 2011, Am J Physiol Gastrointest Liver Physiol Keiffer & Bond, 2014, J Biol Chem

IL-18

Meprin β

Activation of IL-18

Banerjee & Bond, 2008, J Biol Chem

CD99

Meprin β

Cleavage of CD99 induces transendothelial cell migration (TEM)

Bedau et al., 2017, FASEB J

Nidogen 1

Meprin α Meprin β

Cleavage of nidogen-1 in nephrotoxicity

Herzog et al., 2015, Toxicol Lett

Thymosin-β4

Meprin α

Release of anti-inflammatory peptide Ac-SDKP

Kumar et al., 2016, Am J Physiol Renal Physiol

IP

SC R

NU

MA

D

TE

CE P

T

Collagen I

Arnold et al., 2017, Sci Rep

AC

Meprins in physiological ECM remodeling One of the best evaluated functions of meprins in the ECM is the regulation of collagen assembly, whereby meprins are the only known proteases to cleave off the N- and the Cterminal pro-domains of collagen type I and III (Broder et al., 2013) (Fig. 2). This enables fibril formation without additional factors and distinguishes meprins from other collagen processing enzymes which are restricted to either C- or N-terminal cleavage. This role in collagen maturation is supported by the finding that meprin α and β were found upregulated in keloids, fibrotic skin tumors, where ECM is excessively accumulated. In contrast, mice deficient for meprins show decreased collagen deposition in the skin. Collagen type IV was also shown to be cleaved by meprins in vitro (Kruse et al., 2004). This could lead to promotion of immune cell infiltration across the basement membrane upon inflammatory processes, as shown for MMPs 11

ACCEPTED MANUSCRIPT and elastase (Delclaux et al., 1996, Monaco et al., 2006). Other substrates of meprin α and β related to the ECM network are nidogen-1, tenascin-C and fibronectin (Ambort et al., 2010, Kohler et al., 2000, Kruse et al., 2004, Walker et al., 1998). Nidogen-1 and tenascin-C are

IP

T

important basement membrane glycoproteins mediating binding to the ECM. Cleavage of these networks by proteases results in disruption of ECM-binding and often leads to the

SC R

generation of pro-inflammatory fragments. Short-term meprin inhibitor (actinonin) application correlated with decreased excretion of fragmented nidogen-1 upon induced nephrotoxicity in

NU

vivo, which was verified in meprin β-deficient mice (Herzog et al., 2015). Tenascin-C was shown to be cleaved within its anti-adhesive domain by meprin β leading to increased cell

MA

spreading (Ambort et al., 2010). Fibronectin as well as collagen IV were described to not only be degraded by proteases but their cleavage fragments accomplish chemotactic and receptor activating or blocking properties, again underlining the cross-linkage between ECM remodeling

TE

D

and the innate immune system (Adair-Kirk and Senior, 2008). SPARC and fibulin were identified as additional ECM substrates for meprins based on a proteomics approach (Becker-

CE P

Pauly et al., 2011). Here, a meprin mediated cleavage might lead to remodeling via disruption of ECM component binding and/or to the promotion of inflammation. SPARC was suggested to translocate into the nucleus via a pore complex (Yan et al., 2005). Interestingly, distinct

AC

functions of SPARC were identified after proteolytic cleavage into defined polypeptides (Sage et al., 2003) and proteolytic fragments of fibulin-3 serve as clinical markers in osteoarthritis (Runhaar et al., 2016). Meprins cleave inflammatory cytokines and contribute to immune cell extravasation Proteolytic cleavage of ECM and particularly membrane associated proteins is involved in tissue remodeling upon injury, in growth and homeostasis, but can also drive the local infiltration of immune cells. Shedding of adhesion molecules can result in the loss of cell-cell contacts and thereby promotes trans-endothelial migration. Upon inflammation, neutrophils initiate a proteolytic cascade that results in the cleavage of endothelial junction proteins (Pham, 2008). Matrix metalloprotease 2 (MMP-2) was shown to inactivate β1-integrin thereby decreasing cell adhesion during invasion or wound healing (Kryczka et al., 2012). In this line, 12

ACCEPTED MANUSCRIPT we discovered the adhesion molecule CD99 on leukocytes as meprin β substrate (Bedau et al., 2017). Processing of CD99 by meprin β induced cell migration in vitro, thus strongly suggesting a role of this protease in inflammatory processes upon upregulation (Fig. 2).

IP

T

Indeed, full length CD99 accumulated upon meprin inhibition in vivo.

Induction of inflammation by resident immune cells, i.e. macrophages, is followed by the

SC R

release of inflammatory mediators. Meprin β was shown to induce the production of proinflammatory cytokines, including interleukin-1β (IL-1β), interleukin-18 and interleukin-6 (IL-6)

NU

in macrophages (Li et al., 2014). Additionally, interleukin-8 induction was described to be mediated by meprin β in human bronchial epithelial cells (Bergin et al., 2008). Cytokines of the

MA

cytokine family 1 are directly activated by proteases released by neutrophils and mast cells during inflammation (Afonina et al., 2015). Despite the well-described intracellular maturation, IL-1β and IL-18 were proposed to be directly activated by meprin α (Herzog et al., 2009) or

TE

D

meprin β (Banerjee and Bond, 2008), respectively, in vitro. On the other side, cytokines can also be inactivated by proteases. IL-6, a key regulator in inflammation, loses activity in the

CE P

presence of proteases released by activated neutrophils at inflammatory sites (Bank et al., 1999, McGreal et al., 2010). Meprin α and meprin β were also shown to cleave IL-6, thereby abolishing cytokine activity in vitro (Keiffer and Bond, 2014). This is in line with significantly

AC

increased IL-6 protein levels, among other cytokines, in meprin α and meprin β double deficient mice when challenged with dextran sodium sulfate (Banerjee et al., 2011). Shedding of transforming growth factor alpha α (TGF α) and epidermal growth factor (EGF) by meprin α was described to induce EGF receptor/ mitogen-activated protein kinase (EGFR/MAPK) signaling or toll like receptor (TLR) responses (Bergin et al., 2008, Minder et al., 2012). The like-wise pro-inflammatory extracellular signal-regulated kinases (ERK1/2) mediated pathway was described to be indirectly activated by meprin. Here, activation of ADAM10 by meprin β led to ERK1/2-signaling in macrophages (Li et al., 2014). Furthermore, we recently identified the IL-6 cytokine receptor as substrate of meprins. Cleavage of the receptor by soluble meprin α or membrane-bound meprin β at the cell surface leads to proinflammatory trans-signaling of IL-6 (Arnold et al., 2017a) (Fig. 2). 13

ACCEPTED MANUSCRIPT The above described pathways influenced by meprin proteases are known to induce inflammation but also cell proliferation and migration. Hence, evaluating the molecular mechanisms that regulate meprins, described earlier in this review, is crucial to assess

AC

CE P

TE

D

MA

NU

SC R

IP

T

eventual therapeutic approaches.

Figure 2: Secreted and membrane-tethered substrates of meprins. Shedding of the IL-6 receptor (IL-6R) by meprins can induce pro-inflammatory trans-signaling. Cleavage of CD99 by meprin β promotes transendothelial cell migration. Meprin β can be activated by matriptase-2 (MT2) at the cell surface. Metalloproteases ADAM10/17 are sheddases of meprin β. Soluble meprins are activated by soluble tryptic serine proteases.

14

ACCEPTED MANUSCRIPT Meprins in fibrosis Meprin metalloproteases were found to be upregulated in keloids, which are fibrotic skin tumors characterized by pathological ECM formation (Kronenberg et al., 2010). Vice versa, mice

IP

T

deficient for meprin α or meprin β display decreased collagen deposition in the skin correlating with impaired tensile strength (Broder et al., 2013). This resembles the phenotype of certain

SC R

Ehlers-Danlos syndrome patients, with a defect in collagen maturation leading to increased skin extensibility (Byers and Murray, 2014). In a mouse model of systemic inflammation,

NU

induced by bleomycin administration, meprin β was described to support collagen I maturation in the lung (Biasin et al., 2017). Hence, lung fibrosis upon acute lung injury is proposed to be

MA

triggered by alterations in meprin expression. Meprin β was further described as the most upregulated gene in the lung of transgenic mice that serve as a model of idiopathic pulmonary arterial hypertension (IPAH), namely Fra2 mice (Biasin et al., 2014). In IPAH pathology

TE

D

inflammatory processes in the lung of patients correlate with excess deposition of ECM around lung arteries which consequently leads to organ failure within a few years after diagnosis

CE P

(Ahmed and Palevsky, 2014, Montani et al., 2014). Hallmarks of the vascular remodeling in pulmonary hypertension pathology are inflammation as well as increased cell proliferation and ECM turnover (Humbert et al., 2004). Therapies are only effective upon early diagnosis and

AC

mainly target further progression of disease (McLaughlin et al., 2004, Fujimoto et al., 2015, Proudman et al., 2007). In the Fra2-transgenic mouse model, the Fos-related antigen 2 (Fra2) protein is overexpressed which is part of the activator protein-1 (AP-1) heterodimeric transcription complex (Eferl et al., 2008). The AP-1 complex, which is comprised of Fra2 and a Jun protein family member, is described to control transcription of genes involved in vascular lung and connective tissue formation (Eferl et al., 2008). Biasin and colleagues revealed transcriptional regulation of meprin β by Fra2 in primary human smooth muscle cells (PASMCs), to be regulated by TGFβ pro-fibrotic signaling (Biasin et al., 2014). Indeed, Fra2 overexpression was also detected in lung samples of IPAH patients. Additionally, it was shown that underlying systemic sclerosis, an autoimmune disease with fibrotic growth of connective tissues, results in worse prognosis in pulmonary hypertension patients (Chaisson and 15

ACCEPTED MANUSCRIPT Hassoun, 2013, Mathai and Hassoun, 2011) and also the Fra2-transgenic mice resemble this systemic sclerotic phenotype.

T

Meprins in chronic inflammation

IP

Since leukocyte infiltration and the production of pro-inflammatory mediators are promoted by

SC R

meprin activity, this can additionally drive the inflammatory response not only in IPAH patients. Subsequently, cytokine mediated immune response by meprins was connected with other chronic inflammatory diseases, like vasculitis, inflammatory bowel disease (IBD) or renal and

NU

urogenital injury (Banerjee and Bond, 2008, Crisman et al., 2004, Kentsis et al., 2013, Yura et al., 2009). High abundance of meprin α in urine is described as a valuable clinical marker of

MA

Kawasaki disease (KD), an acute vasculitis in children, leading to severe morbidity and without early treatment eventually leading to death (Kentsis et al., 2013). Furthermore, meprin β

D

cleavage of tenascin-C, an adhesion modulating and signal transducing glycoprotein as

TE

described above, correlated with increased cell spreading in vitro und was proposed to have regulatory effects in chronic inflammatory diseases (Ambort et al., 2010). Meprins are

CE P

abundantly expressed in kidney, and high meprin levels in human urine have been correlated with urinary tract infections (Bond et al., 2005). Nephrotoxicity mediated by meprins was also shown in renal tubular cells (Carmago et al., 2002) and in induced acute kidney injury in mice

AC

(Herzog et al., 2015, Yura et al., 2009). These data propose meprins as promising therapeutic targets to restore the balance between inflammation and ECM deposition in severe pathologies (Fig. 3). The above mentioned mouse models for inflammatory diseases represent valuable models for therapeutic studies, particularly Fra2-transgenic mice, since here chronic inflammation is combined with systemic sclerosis.

16

AC

CE P

TE

D

MA

NU

SC R

IP

T

ACCEPTED MANUSCRIPT

Figure 3: Meprins are important proteolytic regulators of inflammatory processes and ECM remodeling. Upon certain stimuli, meprins can induce pro-inflammatory signals that lead to rearrangement of the mesenchymal environment. Invasion of immune cells in such tissues and differentiation of ECM producing cells can result in pathological collagen deposition and fibrosis development.

Therapeutic strategies to inhibit meprin activity General anti-inflammatory therapies have a broad range of applications and are constantly optimized and renewed. Fibrotic diseases, on the other hand, are often treated by targeting growth factors like TGF β (Hawinkels and Ten Dijke, 2011) or administering collagenases directly to keloids and wounds (Alipour et al., 2016, Bae-Harboe et al., 2014). Inhibition of 17

ACCEPTED MANUSCRIPT meprins may be a strategy to not only target the symptoms but additionally prevent the onset of fibrosis. Several inhibitors have been developed against metalloproteases, based on different chemical

IP

T

moieties. Hydroxamate-based inhibitors chelating the zinc-ion are frequently used in research. Among those, actinonin, a naturally occurring compound with antibacterial activity was

SC R

identified as a potent inhibitor for meprin α, but also to a lesser extent for meprin β (Kruse et al., 2004). However, actinonin is rather unspecific, which is shown by its inhibitory capacity

NU

towards leucyl-aminopeptidases (Xu et al., 1998). Although hydroxamate inhibitors possess strong binding-affinities to the catalytic zinc, their stability is metabolically labile and clinical

MA

trials have been disappointing in the past (Vandenbroucke and Libert, 2014). Another class of inhibitors also targeting the zinc within the active site of metalloproteases are for example thiolbased compounds. Selective inhibitors targeting MMP-13 have been developed for

D

osteoarthritis treatment with sulfonate-groups forming salts with the zinc-ion (Hu et al., 2005).

TE

Until now, the most potent inhibitors for meprin β are based on sulfonate-moieties,

CE P

unfortunately still lacking high specificity (Madoux et al., 2014). Phosphorous-based inhibitors in contrast were demonstrated to be highly specific for metalloproteases, mimicking natural substrates in their transition states (Dive et al., 2004). Although they contain peptide bonds in

AC

their chemical structure, phosphinic peptides were shown to be fully stable and non-toxic in vivo (Johnson et al., 2011). Moreover, when compared to other zinc-metalloproteinase inhibitors (thiol, carboxylate or hydroxamates), the whole active site cleft of the proteinase (both primed and unprimed site) can be probed, allowing better inhibitor selectivity. One example is the use of phosphinic peptides directed against MMP-12 that have been shown to reduce inflammation in rheumatoid arthritis in vivo (Marchant et al., 2014). Due to their striking cleavage specificity (Becker-Pauly et al., 2011) meprin metalloproteases are promising candidates for the successful development of specific phosphinic inhibitors. Based on recent findings reviewed in this article, using biochemical and cellular approaches, employing mouse models as well as analysis of human tissues, meprins could indeed be important factors for the onset and progression of chronic inflammation and associated fibrotic 18

ACCEPTED MANUSCRIPT diseases. Future studies will show if the metalloproteases meprin α and meprin β are suitable targets for medical treatment of such conditions.

T

Acknowledgements

IP

We thank Dr. Michelle Rothaug for proofreading. This work was supported by the Deutsche

SC R

Forschungsgemeinschaft (DFG) SFB 877 (Proteolysis as a Regulatory Event in

AC

CE P

TE

D

MA

NU

Pathophysiology, project A9).

19

ACCEPTED MANUSCRIPT References ADAIR-KIRK, T. L. & SENIOR, R. M. 2008. Fragments of extracellular matrix as mediators of

T

inflammation. Int J Biochem Cell Biol, 40, 1101-10.

IP

ADRAIN, C., ZETTL, M., CHRISTOVA, Y., TAYLOR, N. & FREEMAN, M. 2012. Tumor necrosis factor

SC R

signaling requires iRhom2 to promote trafficking and activation of TACE. Science, 335, 225-8. AFONINA, I. S., MULLER, C., MARTIN, S. J. & BEYAERT, R. 2015. Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme. Immunity, 42, 991-1004.

NU

AHMED, S. & PALEVSKY, H. I. 2014. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum Dis Clin North Am, 40, 103-24.

MA

ALIPOUR, H., RAZ, A., ZAKERI, S. & DINPARAST DJADID, N. 2016. Therapeutic applications of collagenase (metalloproteases): A review. Asian Pacific Journal of Tropical Biomedicine, 6, 975-981.

D

AMBORT, D., BRELLIER, F., BECKER-PAULY, C., STOCKER, W., ANDREJEVIC-BLANT, S., CHIQUET, M. &

TE

STERCHI, E. E. 2010. Specific processing of tenascin-C by the metalloprotease meprinbeta

CE P

neutralizes its inhibition of cell spreading. Matrix Biol, 29, 31-42. ARNOLD, P., BOLL, I., ROTHAUG, M., SCHUMACHER, N., SCHMIDT, F., WICHERT, R., SCHNEPPENHEIM, J., LOKAU, J., PICKHINKE, U., KOUDELKA, T., THOLEY, A., RABE, B., SCHELLER, J., LUCIUS, R.,

AC

GARBERS, C., ROSE-JOHN, S. & BECKER-PAULY, C. 2017a. Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling. Sci Rep, 7, 44053. ARNOLD, P., KOOPMANN, L., PETERS, F., BIRKENFELD, F., GOFF, S. V., DAMM, T., QIN, C., MOALI, C., LUCIUS, R. & BECKER-PAULY, C. 2017b. Deficiency of the DSPP-cleaving enzymes meprin alpha and meprin beta does not result in dentin malformation in mice. Cell and tissue research, 367, 351-358. ARNOLD, P., SCHMIDT, F., PROX, J., ZUNKE, F., PIETRZIK, C., LUCIUS, R. & BECKER-PAULY, C. 2015. Calcium negatively regulates meprin beta activity and attenuates substrate cleavage. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 29, 3549-57. 20

ACCEPTED MANUSCRIPT AROLAS, J. L., BRODER, C., JEFFERSON, T., GUEVARA, T., STERCHI, E. E., BODE, W., STOCKER, W., BECKER-PAULY, C. & GOMIS-RUTH, F. X. 2012. Structural basis for the sheddase function of

T

human meprin beta metalloproteinase at the plasma membrane. Proceedings of the National

IP

Academy of Sciences of the United States of America, 109, 16131-6.

SC R

BAE-HARBOE, Y. S., HARBOE-SCHMIDT, J. E., GRABER, E. & GILCHREST, B. A. 2014. Collagenase followed by compression for the treatment of earlobe keloids. Dermatol Surg, 40, 519-24. BANERJEE, S. & BOND, J. S. 2008. Prointerleukin-18 is activated by meprin beta in vitro and in vivo in

NU

intestinal inflammation. J Biol Chem, 283, 31371-7.

BANERJEE, S., JIN, G., BRADLEY, S. G., MATTERS, G. L., GAILEY, R. D., CRISMAN, J. M. & BOND, J. S. 2011.

MA

Balance of meprin A and B in mice affects the progression of experimental inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol, 300, G273-82.

D

BANK, U., KUPPER, B., REINHOLD, D., HOFFMANN, T. & ANSORGE, S. 1999. Evidence for a crucial role

TE

of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of

CE P

inflammation. FEBS Lett, 461, 235-40. BECKER-PAULY, C., BARRE, O., SCHILLING, O., AUF DEM KELLER, U., OHLER, A., BRODER, C., SCHUTTE, A., KAPPELHOFF, R., STOCKER, W. & OVERALL, C. M. 2011. Proteomic analyses reveal an acidic

AC

prime side specificity for the astacin metalloprotease family reflected by physiological substrates. Mol Cell Proteomics, 10, M111 009233. BECKER, C., KRUSE, M. N., SLOTTY, K. A., KOHLER, D., HARRIS, J. R., ROSMANN, S., STERCHI, E. E. & STOCKER, W. 2003. Differences in the activation mechanism between the alpha and beta subunits of human meprin. Biological chemistry, 384, 825-31. BEDAU, T., PETERS, F., PROX, J., ARNOLD, P., SCHMIDT, F., FINKERNAGEL, M., KOLLMANN, S., WICHERT, R., OTTE, A., OHLER, A., STIRNBERG, M., LUCIUS, R., KOUDELKA, T., THOLEY, A., BIASIN, V., PIETRZIK, C. U., KWAPISZEWSKA, G. & BECKER-PAULY, C. 2017. Ectodomain shedding of CD99 within highly conserved regions is mediated by the metalloprotease meprin beta and promotes transendothelial cell migration. FASEB J, 31, 1226-1237. 21

ACCEPTED MANUSCRIPT BERGIN, D. A., GREENE, C. M., STERCHI, E. E., KENNA, C., GERAGHTY, P., BELAAOUAJ, A., TAGGART, C. C., O'NEILL, S. J. & MCELVANEY, N. G. 2008. Activation of the epidermal growth factor receptor

T

(EGFR) by a novel metalloprotease pathway. J Biol Chem, 283, 31736-44.

IP

BERTENSHAW, G. P., NORCUM, M. T. & BOND, J. S. 2003. Structure of homo- and hetero-oligomeric

SC R

meprin metalloproteases. Dimers, tetramers, and high molecular mass multimers. The Journal of biological chemistry, 278, 2522-32.

BHOGAL, R. K., STOICA, C. M., MCGAHA, T. L. & BONA, C. A. 2005. Molecular aspects of regulation of

NU

collagen gene expression in fibrosis. J Clin Immunol, 25, 592-603. BIASIN, V., MARSH, L. M., EGEMNAZAROV, B., WILHELM, J., GHANIM, B., KLEPETKO, W., WYGRECKA,

MA

M., OLSCHEWSKI, H., EFERL, R., OLSCHEWSKI, A. & KWAPISZEWSKA, G. 2014. Meprin beta, a novel mediator of vascular remodelling underlying pulmonary hypertension. J Pathol, 233, 7-

D

17.

TE

BIASIN, V., WYGRECKA, M., MARSH, L. M., BECKER-PAULY, C., BRCIC, L., GHANIM, B., KLEPETKO, W.,

CE P

OLSCHEWSKI, A. & KWAPISZEWSKA, G. 2017. Meprin beta contributes to collagen deposition in lung fibrosis. Sci Rep, 7, 39969. BIEN, J., JEFFERSON, T., CAUSEVIC, M., JUMPERTZ, T., MUNTER, L., MULTHAUP, G., WEGGEN, S.,

AC

BECKER-PAULY, C. & PIETRZIK, C. U. 2012. The metalloprotease meprin beta generates amino terminal-truncated amyloid beta peptide species. The Journal of biological chemistry, 287, 33304-13. BOND, J. S., MATTERS, G. L., BANERJEE, S. & DUSHECK, R. E. 2005. Meprin metalloprotease expression and regulation in kidney, intestine, urinary tract infections and cancer. FEBS Lett, 579, 331722. BREIG, O., YATES, M., NEAUD, V., COUCHY, G., GRIGOLETTO, A., LUCCHESI, C., PROX, J., ZUCMANROSSI, J., BECKER-PAULY, C. & ROSENBAUM, J. 2017. Metalloproteinase meprin alpha regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. Oncotarget, 8, 7839-7851. 22

ACCEPTED MANUSCRIPT BRODER, C., ARNOLD, P., VADON-LE GOFF, S., KONERDING, M. A., BAHR, K., MULLER, S., OVERALL, C. M., BOND, J. S., KOUDELKA, T., THOLEY, A., HULMES, D. J., MOALI, C. & BECKER-PAULY, C. 2013.

T

Metalloproteases meprin alpha and meprin beta are C- and N-procollagen proteinases

IP

important for collagen assembly and tensile strength. Proc Natl Acad Sci U S A, 110, 14219-24.

SC R

BRODER, C. & BECKER-PAULY, C. 2013. The metalloproteases meprin alpha and meprin beta: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. The Biochemical journal, 450, 253-64.

NU

BYERS, P. H. & MURRAY, M. L. 2014. Ehlers-Danlos syndrome: a showcase of conditions that lead to understanding matrix biology. Matrix Biol, 33, 10-5.

MA

CARMAGO, S., SHAH, S. V. & WALKER, P. D. 2002. Meprin, a brush-border enzyme, plays an important role in hypoxic/ischemic acute renal tubular injury in rats. Kidney Int, 61, 959-66.

D

CHAISSON, N. F. & HASSOUN, P. M. 2013. Systemic sclerosis-associated pulmonary arterial

TE

hypertension. Chest, 144, 1346-56.

CE P

COULOUARN, C. & CLEMENT, B. 2014. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. Journal of hepatology, 60, 1306-9. CRISMAN, J. M., ZHANG, B., NORMAN, L. P. & BOND, J. S. 2004. Deletion of the mouse meprin beta

AC

metalloprotease gene diminishes the ability of leukocytes to disseminate through extracellular matrix. J Immunol, 172, 4510-9. DELCLAUX, C., DELACOURT, C., D'ORTHO, M. P., BOYER, V., LAFUMA, C. & HARF, A. 1996. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol, 14, 288-95. DIVE, V., GEORGIADIS, D., MATZIARI, M., MAKARITIS, A., BEAU, F., CUNIASSE, P. & YIOTAKIS, A. 2004. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell Mol Life Sci, 61, 2010-9. EFERL, R., HASSELBLATT, P., RATH, M., POPPER, H., ZENZ, R., KOMNENOVIC, V., IDARRAGA, M. H., KENNER, L. & WAGNER, E. F. 2008. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A, 105, 10525-30. 23

ACCEPTED MANUSCRIPT FORTELNY, N., COX, J. H., KAPPELHOFF, R., STARR, A. E., LANGE, P. F., PAVLIDIS, P. & OVERALL, C. M. 2014. Network analyses reveal pervasive functional regulation between proteases in the

T

human protease web. PLoS biology, 12, e1001869.

IP

FUJIMOTO, H., KOBAYASHI, T. & AZUMA, A. 2015. Idiopathic Pulmonary Fibrosis: Treatment and

SC R

Prognosis. Clin Med Insights Circ Respir Pulm Med, 9, 179-185.

HAHN, D., PISCHITZIS, A., ROESMANN, S., HANSEN, M. K., LEUENBERGER, B., LUGINBUEHL, U. & STERCHI, E. E. 2003. Phorbol 12-myristate 13-acetate-induced ectodomain shedding and

NU

phosphorylation of the human meprinbeta metalloprotease. The Journal of biological chemistry, 278, 42829-39.

MA

HAWINKELS, L. J. & TEN DIJKE, P. 2011. Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors, 29, 140-52.

D

HERZOG, C., HAUN, R. S., KAUSHAL, V., MAYEUX, P. R., SHAH, S. V. & KAUSHAL, G. P. 2009. Meprin A

TE

and meprin alpha generate biologically functional IL-1beta from pro-IL-1beta. Biochem Biophys

CE P

Res Commun, 379, 904-8.

HERZOG, C., MARISIDDAIAH, R., HAUN, R. S. & KAUSHAL, G. P. 2015. Basement membrane protein nidogen-1 is a target of meprin beta in cisplatin nephrotoxicity. Toxicol Lett, 236, 110-6.

AC

HU, Y., XIANG, J. S., DIGRANDI, M. J., DU, X., IPEK, M., LAAKSO, L. M., LI, J., LI, W., RUSH, T. S., SCHMID, J., SKOTNICKI, J. S., TAM, S., THOMASON, J. R., WANG, Q. & LEVIN, J. I. 2005. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem, 13, 6629-44. HUMBERT, M., MORRELL, N. W., ARCHER, S. L., STENMARK, K. R., MACLEAN, M. R., LANG, I. M., CHRISTMAN, B. W., WEIR, E. K., EICKELBERG, O., VOELKEL, N. F. & RABINOVITCH, M. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol, 43, 13S-24S. JACKLE, F., SCHMIDT, F., WICHERT, R., ARNOLD, P., PROX, J., MANGOLD, M., OHLER, A., PIETRZIK, C. U., KOUDELKA, T., THOLEY, A., GUTSCHOW, M., STIRNBERG, M. & BECKER-PAULY, C. 2015. 24

ACCEPTED MANUSCRIPT Metalloprotease meprin beta is activated by transmembrane serine protease matriptase-2 at the cell surface thereby enhancing APP shedding. The Biochemical journal, 470, 91-103.

T

JEFFERSON, T., AUF DEM KELLER, U., BELLAC, C., METZ, V. V., BRODER, C., HEDRICH, J., OHLER, A.,

IP

MAIER, W., MAGDOLEN, V., STERCHI, E., BOND, J. S., JAYAKUMAR, A., TRAUPE, H., CHALARIS,

SC R

A., ROSE-JOHN, S., PIETRZIK, C. U., POSTINA, R., OVERALL, C. M. & BECKER-PAULY, C. 2013. The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin beta and ADAM10. Cellular and molecular life sciences : CMLS, 70, 309-33.

NU

JOHNSON, J. L., DWIVEDI, A., SOMERVILLE, M., GEORGE, S. J. & NEWBY, A. C. 2011. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration

MA

and neointima formation in mice. Arterioscler Thromb Vasc Biol, 31, e35-44. KEIFFER, T. R. & BOND, J. S. 2014. Meprin metalloproteases inactivate interleukin 6. J Biol Chem, 289,

D

7580-8.

TE

KENTSIS, A., SHULMAN, A., AHMED, S., BRENNAN, E., MONUTEAUX, M. C., LEE, Y. H., LIPSETT, S.,

CE P

PAULO, J. A., DEDEOGLU, F., FUHLBRIGGE, R., BACHUR, R., BRADWIN, G., ARDITI, M., SUNDEL, R. P., NEWBURGER, J. W., STEEN, H. & KIM, S. 2013. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med, 5, 210-20.

AC

KOHLER, D., KRUSE, M., STOCKER, W. & STERCHI, E. E. 2000. Heterologously overexpressed, affinitypurified human meprin alpha is functionally active and cleaves components of the basement membrane in vitro. FEBS Lett, 465, 2-7. KRONENBERG, D., BRUNS, B. C., MOALI, C., VADON-LE GOFF, S., STERCHI, E. E., TRAUPE, H., BOHM, M., HULMES, D. J., STOCKER, W. & BECKER-PAULY, C. 2010. Processing of procollagen III by meprins: new players in extracellular matrix assembly? J Invest Dermatol, 130, 2727-35. KRUSE, M. N., BECKER, C., LOTTAZ, D., KOHLER, D., YIALLOUROS, I., KRELL, H. W., STERCHI, E. E. & STOCKER, W. 2004. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J, 378, 383-9.

25

ACCEPTED MANUSCRIPT KRYCZKA, J., STASIAK, M., DZIKI, L., MIK, M., DZIKI, A. & CIERNIEWSKI, C. 2012. Matrix metalloproteinase-2 cleavage of the beta1 integrin ectodomain facilitates colon cancer cell

T

motility. J Biol Chem, 287, 36556-66.

IP

LI, Y. J., FAN, Y. H., TANG, J., LI, J. B. & YU, C. H. 2014. Meprin-beta regulates production of pro-

SC R

inflammatory factors via a disintegrin and metalloproteinase-10 (ADAM-10) dependent pathway in macrophages. Int Immunopharmacol, 18, 77-84.

MADOUX, F., TREDUP, C., SPICER, T. P., SCAMPAVIA, L., CHASE, P. S., HODDER, P. S., FIELDS, G. B.,

NU

BECKER-PAULY, C. & MINOND, D. 2014. Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin alpha and beta. Biopolymers, 102, 396-

MA

406.

MARCHAND, P., TANG, J., JOHNSON, G. D. & BOND, J. S. 1995. COOH-terminal proteolytic processing

D

of secreted and membrane forms of the alpha subunit of the metalloprotease meprin A.

TE

Requirement of the I domain for processing in the endoplasmic reticulum. The Journal of

CE P

biological chemistry, 270, 5449-56. MARCHANT, D. J., BELLAC, C. L., MORAES, T. J., WADSWORTH, S. J., DUFOUR, A., BUTLER, G. S., BILAWCHUK, L. M., HENDRY, R. G., ROBERTSON, A. G., CHEUNG, C. T., NG, J., ANG, L., LUO, Z.,

AC

HEILBRON, K., NORRIS, M. J., DUAN, W., BUCYK, T., KARPOV, A., DEVEL, L., GEORGIADIS, D., HEGELE, R. G., LUO, H., GRANVILLE, D. J., DIVE, V., MCMANUS, B. M. & OVERALL, C. M. 2014. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nature medicine, 20, 493-502. MATHAI, S. C. & HASSOUN, P. M. 2011. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med, 5, 267-79. MATTHEWS, A. L., NOY, P. J., REYAT, J. S. & TOMLINSON, M. G. 2016. Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids. Platelets, 1-9.

26

ACCEPTED MANUSCRIPT MCGREAL, E. P., DAVIES, P. L., POWELL, W., ROSE-JOHN, S., SPILLER, O. B., DOULL, I., JONES, S. A. & KOTECHA, S. 2010. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine

T

proteases in cystic fibrosis. Biochim Biophys Acta, 1802, 649-58.

IP

MCILWAIN, D. R., LANG, P. A., MARETZKY, T., HAMADA, K., OHISHI, K., MANEY, S. K., BERGER, T.,

SC R

MURTHY, A., DUNCAN, G., XU, H. C., LANG, K. S., HAUSSINGER, D., WAKEHAM, A., ITIE-YOUTEN, A., KHOKHA, R., OHASHI, P. S., BLOBEL, C. P. & MAK, T. W. 2012. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science, 335, 229-32.

NU

MCLAUGHLIN, V. V., PRESBERG, K. W., DOYLE, R. L., ABMAN, S. H., MCCRORY, D. C., FORTIN, T., AHEARN, G. & AMERICAN COLLEGE OF CHEST, P. 2004. Prognosis of pulmonary arterial

MA

hypertension: ACCP evidence-based clinical practice guidelines. Chest, 126, 78S-92S. MINDER, P., BAYHA, E., BECKER-PAULY, C. & STERCHI, E. E. 2012. Meprinalpha transactivates the

D

epidermal growth factor receptor (EGFR) via ligand shedding, thereby enhancing colorectal

TE

cancer cell proliferation and migration. J Biol Chem, 287, 35201-11.

CE P

MONACO, S., SPARANO, V., GIOIA, M., SBARDELLA, D., DI PIERRO, D., MARINI, S. & COLETTA, M. 2006. Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci, 15, 2805-15.

AC

MONTANI, D., CHAUMAIS, M. C., GUIGNABERT, C., GUNTHER, S., GIRERD, B., JAIS, X., ALGALARRONDO, V., PRICE, L. C., SAVALE, L., SITBON, O., SIMONNEAU, G. & HUMBERT, M. 2014. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther, 141, 172-91. MUIR, A. M., REN, Y., BUTZ, D. H., DAVIS, N. A., BLANK, R. D., BIRK, D. E., LEE, S. J., ROWE, D., FENG, J. Q. & GREENSPAN, D. S. 2014. Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice. Human molecular genetics, 23, 3085-101. OHLER, A., DEBELA, M., WAGNER, S., MAGDOLEN, V. & BECKER-PAULY, C. 2010. Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biological chemistry, 391, 455-60. 27

ACCEPTED MANUSCRIPT PHAM, C. T. 2008. Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell Biol, 40, 1317-33.

T

PROUDMAN, S. M., STEVENS, W. M., SAHHAR, J. & CELERMAJER, D. 2007. Pulmonary arterial

IP

hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J,

SC R

37, 485-94.

PROX, J., ARNOLD, P. & BECKER-PAULY, C. 2015. Meprin alpha and meprin beta: Procollagen proteinases in health and disease. Matrix biology : journal of the International Society for

NU

Matrix Biology, 44-46, 7-13.

ROSMANN, S., HAHN, D., LOTTAZ, D., KRUSE, M. N., STOCKER, W. & STERCHI, E. E. 2002. Activation of

MA

human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen-activating system. The Journal of biological chemistry, 277, 40650-8.

D

RUNHAAR, J., SANCHEZ, C., TARALLA, S., HENROTIN, Y. & BIERMA-ZEINSTRA, S. M. 2016. Fibulin-3

TE

fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese

CE P

women. Osteoarthritis Cartilage, 24, 672-8. SAGE, E. H., REED, M., FUNK, S. E., TRUONG, T., STEADELE, M., PUOLAKKAINEN, P., MAURICE, D. H. & BASSUK, J. A. 2003. Cleavage of the matricellular protein SPARC by matrix metalloproteinase

AC

3 produces polypeptides that influence angiogenesis. J Biol Chem, 278, 37849-57. SCHMIDT, F., MULLER, M., PROX, J., ARNOLD, P., SCHONHERR, C., TREDUP, C., MINDER, P., EBSEN, H., JANSSEN, O., ANNAERT, W., PIETRZIK, C., SCHMIDT-ARRAS, D., STERCHI, E. E. & BECKER-PAULY, C. 2016. Tetraspanin 8 is an interactor of the metalloprotease meprin beta within tetraspaninenriched microdomains. Biological chemistry. SCHNEPPENHEIM, J., SCHARFENBERG, F., LUCIUS, R., BECKER-PAULY, C. & ARNOLD, P. 2017. Meprin beta and BMP-1 are differentially regulated by CaCl2. Cell calcium. SCHONHERR, C., BIEN, J., ISBERT, S., WICHERT, R., PROX, J., ALTMEPPEN, H., KUMAR, S., WALTER, J., LICHTENTHALER, S. F., WEGGEN, S., GLATZEL, M., BECKER-PAULY, C. & PIETRZIK, C. U. 2016. Generation of aggregation prone N-terminally truncated amyloid beta peptides by meprin 28

ACCEPTED MANUSCRIPT beta depends on the sequence specificity at the cleavage site. Molecular neurodegeneration, 11, 19.

T

SCHUTTE, A., ERMUND, A., BECKER-PAULY, C., JOHANSSON, M. E., RODRIGUEZ-PINEIRO, A. M.,

IP

BACKHED, F., MULLER, S., LOTTAZ, D., BOND, J. S. & HANSSON, G. C. 2014. Microbial-induced

SC R

meprin beta cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus. Proceedings of the National Academy of Sciences of the United States of America, 111, 12396-401.

NU

SOMLYO, A. P., BOND, M. & SOMLYO, A. V. 1985. Calcium content of mitochondria and endoplasmic reticulum in liver frozen rapidly in vivo. Nature, 314, 622-5.

MA

TROJANOWSKA, M., LEROY, E. C., ECKES, B. & KRIEG, T. 1998. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med (Berl), 76, 266-74.

D

TSUCHIYA, S., SIMMER, J. P., HU, J. C., RICHARDSON, A. S., YAMAKOSHI, F. & YAMAKOSHI, Y. 2011.

TE

Astacin proteases cleave dentin sialophosphoprotein (Dspp) to generate dentin

CE P

phosphoprotein (Dpp). Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 26, 220-8. VANDENBROUCKE, R. E. & LIBERT, C. 2014. Is there new hope for therapeutic matrix metalloproteinase

AC

inhibition? Nat Rev Drug Discov, 13, 904-27. VASSAR, R., KUHN, P. H., HAASS, C., KENNEDY, M. E., RAJENDRAN, L., WONG, P. C. & LICHTENTHALER, S. F. 2014. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. Journal of neurochemistry, 130, 4-28. WALKER, P. D., KAUSHAL, G. P. & SHAH, S. V. 1998. Meprin A, the major matrix degrading enzyme in renal tubules, produces a novel nidogen fragment in vitro and in vivo. Kidney Int, 53, 1673-80. WANG, J., MASSOUDI, D., REN, Y., MUIR, A. M., HARRIS, S. E., GREENSPAN, D. S. & FENG, J. Q. 2017. BMP1 and TLL1 Are Required for Maintaining Periodontal Homeostasis. Journal of dental research, 22034516686558.

29

ACCEPTED MANUSCRIPT XU, Y., LAI, L. T., GABRILOVE, J. L. & SCHEINBERG, D. A. 1998. Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res, 4, 171-6.

T

YAN, Q., WEAVER, M., PERDUE, N. & SAGE, E. H. 2005. Matricellular protein SPARC is translocated to

IP

the nuclei of immortalized murine lens epithelial cells. J Cell Physiol, 203, 286-94.

SC R

YURA, R. E., BRADLEY, S. G., RAMESH, G., REEVES, W. B. & BOND, J. S. 2009. Meprin A metalloproteases enhance renal damage and bladder inflammation after LPS challenge. Am J Physiol Renal

AC

CE P

TE

D

MA

NU

Physiol, 296, F135-44.

30

ACCEPTED MANUSCRIPT Highlights - Review of latest research on the metalloproteases meprin α and meprin β in health and disease.

IP

T

- New aspects of molecular regulation of meprins that influence proteolytic activity and

SC R

cellular localization.

- Summary of physiological functions of meprins in extracellular matrix remodeling and

NU

inflammation.

AC

CE P

TE

D

MA

- Dysregulation of meprins is associated with chronic inflammation and fibrosis.

31